Corcept Therapeutics (Corcept Therapeutics) Short-Term Debt & Capital Lease Obligation : $0.2 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Corcept Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.2 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Corcept Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil.

Corcept Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Corcept Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Corcept Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

1.56

2.05

0.53

1.14

0.15

Corcept Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1.14	0.58	0.30	0.23	0.15

Corcept Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Corcept Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Corcept Therapeutics (Corcept Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

HTD:Germany

Address

149 Commonwealth Drive, Menlo Park, CA, USA, 94025

Website

https://www.corcept.com

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Executives

Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer	officer: Chief Development Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb	officer: CHIEF FINANCIAL OFFICER	C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon	officer: Chief Accounting Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck	officer: See Remarks	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt	officer: Chief Scientific Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff	director, officer: CHIEF EXECUTIVE OFFICER	149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr	director, 10 percent owner	755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer	officer: Chief Medical Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025